Kanał KRRO
KR

Korro Bio, Inc.

KRRO · NASDAQ

$14.07 +1.44% (+$0.20)
1M +7.08%
Market Cap $140.0M
P/E Ratio -
Div. Yield -
ROE 114.26%
Piotroski F-Score Weak
2/9
Valuation
50 /100
Fair
P/B 1.36x
P/S 58.79x
PEG N/A
Growth
-
N/A
Book val. growth N/A
FCF growth N/A
EPS growth N/A
Profitability
20 /100
Weak
FCF margin 2,865.87%
Op. margin 3,176.57%
Gross margin 72.75%
Quality
0 /100
Poor
Asset turnover 0.01x
ROA 65.25%
ROIC 49.60%
Debt
94 /100
Low
Current ratio 9.55x
Debt/Equity 0.41x
Net debt/EBITDA N/A
Stability
9 /100
Unstable
EPS volatility 65.13%
Profitable years 0
Beta 2.25x

Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej

Zapytaj StockBota o KRRO
Online

O spółce

Korro Bio, Inc. (KORO) is an American biotechnology company focused on developing innovative therapeutic approaches in the field of gene therapy and gene editing. With the goal of treating genetic diseases and other complex illnesses using advanced CRISPR technologies and gene editing, Korro Bio is a key player in the biomedicine sector. The company develops therapeutics aimed at modifying the genetic code, which may lead to new treatment options for patients. Korro Bio collaborates with leading scientific institutions and pharmaceutical companies to accelerate the development and commercialization of its products. Korro Bio, Inc. (KORO) shares could be suitable for investors looking to invest in biotechnology with potential for revolutionary advancements in treating genetic diseases.

Opis nie jest jeszcze dostępny w Twoim języku, więc tekst jest po angielsku.

Sector

Healthcare

Industry

Biotechnology

CEO

Ram Aiyar

Employees

57

Headquarters

Cambridge

Nadchodzące wydarzenia

11 LIS

Earnings

Upcoming earnings report

56d

Używamy niezbędnych plików cookie do działania strony oraz opcjonalnych analitycznych plików cookie do pomiaru ruchu. Zobacz naszą Politykę prywatności.